Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1230 of 6351
-
Can a new device change how we treat this condition?
Disease control Details not publishedSponsor: [Redacted] • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New Virus-Based therapy offered to bladder cancer patients who failed standard care
Disease control Expanded accessThis is an open-label, expanded access trial designed to provide access to cretostimogene in patients with NMIBC (specifically CIS with or without HG Ta/T1) unresponsive to BCG.
Sponsor: CG Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Last-Resort cancer therapy made available to patients with no other options
Disease control Expanded accessThe purpose of this registration is to list Managed Access Programs (MAPs) related to CTL019, Tisagenlecleucel
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Zapping tumors: electric fields tested against pancreatic cancer
Disease control Expanded access (paused)The EF-54 program (PANOVA-3CA) is a continued access program for adults with locally advanced pancreatic cancer to access TTFields therapy in combination with gemcitabine and nab-paclitaxel. The purpose of the program is to allow eligible patients to have access to TTFields while…
Sponsor: NovoCure GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New hope for dravet syndrome: expanded access to seizure drug stiripentol
Disease control ApprovedExpanded access to Stiripentol for patients with Dravet Syndrome.
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Can a new device change how we treat disease?
Disease control Details not publishedSponsor: [Redacted] • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Can a novel device tame disease symptoms?
Disease control Details not publishedSponsor: [Redacted] • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Stem cell hope for Parkinson's: expanded access trial offers treatment to 11 patients
Disease control Expanded access (ended)This expanded access protocol is part of IND 027396 to evaluate efficacy and safety of multiple intravenous administrations of autologous HB-adMSCs for the treatment of Parkinson's disease for up to 11 patients who passed pre-screening, completed screening, and were not randomize…
Sponsor: Hope Biosciences Research Foundation • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Experimental Immune-Boosting drug now available for bone cancer patients
Disease control Expanded accessThis expanded access protocol will allow access to treatment with L-MTP-PE for people with osteosarcoma. L-MTP-PE is an investigational drug that has not been approved by the FDA to treat any condition, including osteosarcoma. L-MTP-PE works by activating certain types of white b…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Second chance: Out-of-Spec cancer therapy offered to desperate patients
Disease control Expanded accessThe objective of this expanded access protocol is to provide access to Out Of Specification (OOS) AMTAGVI treatment to patients.
Sponsor: Iovance Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New drug option for Hard-to-Treat cancers with FGFR3 mutations
Disease control Expanded accessThe treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Experimental drug opens door for rare sarcoma patients with no options left
Disease control Expanded access (ended)A multicenter, open-label expanded access program to provide access to tazemetostat to Epithelioid Sarcoma (ES) patients in serious need who are otherwise unable to participate in a clinical study or whom access is not available through marketed product in the US.
Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Can an unapproved device change treatment?
Disease control Details not publishedSponsor: [Redacted] • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a new device tame the disease?
Disease control Details not publishedSponsor: [Redacted] • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Could a new drug offer hope for Treatment-Resistant depression?
Disease control Expanded access (ended)To provide expanded access of esmethadone (REL-1017) to patients with a serious or immediately life-threatening disease or condition that may potentially benefit from esmethadone (REL-1017) who do not have access to other effective therapy and are not eligible for other clinical …
Sponsor: Relmada Therapeutics, Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a new device change disease management?
Disease control Details not publishedSponsor: [Redacted] • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a novel device tame disease? a trial seeks answers
Disease control Details not publishedSponsor: [Redacted] • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Eczema breakthrough: bacteria removal may reduce skin flares
Disease control Not yet recruitingOur hypothesis is that S. aureus skin decolonization in atopic dermatitis reduces disease severity and favorably alters the function and gene expression of epidermal and immune skin cells that contribute to disease severity.
Phase 4 • Sponsor: Boston Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Can a pill rewrite the genetic story of resistant kidney cancer?
Knowledge-focused Not yet recruitingThis is a single-institution, pilot study of oral casdatifan, a selective HIF-2α inhibitor, in patients with metastatic clear cell renal cell carcinoma refractory to prior IO- and VEGF-based therapies. The study will assess changes in HIF2-regulated gene expression through RNA se…
Early phase 1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Knowledge-focused
Last updated Aug 21, 2026 00:00 UTC
-
Can mindfulness stop psychosis before it starts?
Prevention Not yet recruitingThe main objective is to evaluate the efficacy of a group-based mindfulness therapy programme in reducing distress associated with symptoms of UHR (Ultra High Risk) or FEP (first psychotic episode) compared with usual treatment. The secondary objectives were to study the efficacy…
Sponsor: Centre Psychothérapique de Nancy • Aim: Prevention
Last updated Jun 27, 2026 12:00 UTC